Evidence map›Paper›PMID 40977890›Full record

ReviewFrontiers in cell and developmental biology2025

Ferroptosis and bone metabolic diseases: the dual regulatory role of the Nrf2/HO-1 signaling axis.

Wei Nan, Wen-Ming Zhou, Jian-Lan Zi, Yong-Qiang Shi, Yan-Bo Dong, Wei Song, Yan-Chao Ma, Hai-Hong Zhang

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei Nan *The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Wen-Ming Zhou *The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Jian-Lan ZiThe People's Hospital Of Chuxiong Yi Autonomous Prefecture, Chuxiong, China.
Yong-Qiang ShiThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Yan-Bo DongThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Wei SongThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Yan-Chao MaThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Hai-Hong ZhangThe Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a pivotal mechanism in bone disorders including osteoporosis and osteonecrosis. The nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling axis plays a paradoxical role-contributing to cytoprotection under oxidative stress, yet potentially promoting ferroptosis through excessive iron accumulation. This review summarizes how the Nrf2/HO-1 pathway modulates ferroptosis across osteoblasts, osteoclasts, and osteocytes, and its impact on bone homeostasis. We explore the pathway's involvement in the shift from physiological bone remodeling to pathological bone loss. Given its dual role, the Nrf2/HO-1 axis represents both a challenge and an opportunity for therapeutic intervention. Understanding its context-specific functions is essential for developing precise, ferroptosis-targeted strategies in bone disease treatment.

Indexed as

bone homeostasisferroptosisHO-1Nrf2oxidative stress

Identifiers

PMID40977890
PMCPMC12446312

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.